NXTC vs. ENTX, GNTA, SCLX, SKYE, KPTI, CUE, GNLX, BLUE, IPSC, and EPRX
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Entera Bio (ENTX), Genenta Science (GNTA), Scilex (SCLX), Skye Bioscience (SKYE), Karyopharm Therapeutics (KPTI), Cue Biopharma (CUE), Genelux (GNLX), bluebird bio (BLUE), Century Therapeutics (IPSC), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry.
NextCure vs.
Entera Bio (NASDAQ:ENTX) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.
NextCure's return on equity of -62.50% beat Entera Bio's return on equity.
In the previous week, Entera Bio had 1 more articles in the media than NextCure. MarketBeat recorded 1 mentions for Entera Bio and 0 mentions for NextCure. Entera Bio's average media sentiment score of 1.45 beat NextCure's score of -0.06 indicating that Entera Bio is being referred to more favorably in the media.
Entera Bio received 99 more outperform votes than NextCure when rated by MarketBeat users. Likewise, 67.55% of users gave Entera Bio an outperform vote while only 64.52% of users gave NextCure an outperform vote.
Entera Bio presently has a consensus price target of $10.00, suggesting a potential upside of 327.35%. NextCure has a consensus price target of $4.00, suggesting a potential upside of 406.97%. Given NextCure's higher possible upside, analysts plainly believe NextCure is more favorable than Entera Bio.
Entera Bio has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, NextCure has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Entera Bio has higher revenue and earnings than NextCure. Entera Bio is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
14.1% of Entera Bio shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 10.9% of Entera Bio shares are held by insiders. Comparatively, 13.3% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Entera Bio beats NextCure on 8 of the 15 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
This page (NASDAQ:NXTC) was last updated on 1/20/2025 by MarketBeat.com Staff
Free NXTC Stock Alerts